Early Detection of White Matter Integrity Changes in Down Syndrome: The Promise of PSMD as a Sensitive Biomarker

Topic: Brain proteins, microglia and lab models

Abstract Background Down syndrome (DS) is a genetic condition associated with an ultra‐high risk of developing Alzheimer's disease (AD). While vascular risk factors (VRF) are less prevalent in DS, radiological hallmarks of small vessel disease (SVD) are commonly observed. The peak width of skeletonized mean diffusivity (PSMD) is a diffusion tensor imaging (DTI) marker designed to quantify the white matter (WM) damage secondary to cerebral SVD. Here, we aimed to characterize PSMD alterations along the AD continuum in DS and define associations with AD and SVD biomarkers. Method Cross‐sectional study using the Sant Pau Initiative on Neurodegeneration (SPIN) and Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) cohorts. We included 70 euploid healthy controls (HC; median age [IQR]=54.37 [9.03] years, females=70%), and 140 individuals with DS (age=44.15 [17.33] years, females=47.14%), including 92 asymptomatic (aDS), 28 prodromal AD (pDS), and 20 with AD dementia (dDS), underwent a 3T‐MRI protocol. DTI images were visually inspected, and PSMD was extracted using a fully automated pipeline (Baykara et al., 2016). Non‐parametric tests were used to assess the effect of sociodemographic (age, sex, intellectual disability) and genetic (APOE haplotype) factors, VRF (hypertension, dyslipidemia, diabetes mellitus), and AD disease severity on PSMD. Associations with AD biomarkers (Aβ42/Aβ40 ratio, pTau181, and NfL in cerebrospinal fluid [CSF]) and SVD markers (WM hyperintensities [WMH] and microbleeds) were evaluated. Result PSMD was more strongly associated with age in DS (rho=0.56; p <0.001) than in HC (rho=0.38, p <0.001; Figure 1A), with regression lines starting to diverge at age 42. No significant effects were found for sex, APOEε4 status, intellectual disability, or VRF (Figure 1C‐D‐E). PSMD increased linearly along the AD continuum (HC p = 0.003, Figure 2D) and strongly correlated with WMH (rho=0.56, p <0.001; Figure 2E). Conclusion In DS, PSMD changed approximately 10‐15 years before the onset of AD symptoms and linearly increased with AD clinical stages, AD pathology, and SVD metrics. These findings underscore the potential of PSMD as a sensitive biomarker for detecting early WM alterations in adults with DS.

@article{morcillonieto2025-89e62d72,
  author  = {Morcillo-Nieto, Alejandra Omaira and Arriola‐Infante, José Enrique and Franquesa‐Mullerat, María and Zsadanyi, Sára E. and Vaqué‐Alcázar, Lídia and Aranha, Mateus Rozalem and Parra, Jose Allende and Zhao, Zili and others},
  title   = {{Early Detection of White Matter Integrity Changes in Down Syndrome: The Promise of PSMD as a Sensitive Biomarker}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_106537},
  url     = {https://doi.org/10.1002/alz70856_106537}
}

Key findings

• Abstract Background Down syndrome (DS) is a genetic condition associated with an ultra‐high risk of developing Alzheimer's disease (AD).
• Result PSMD was more strongly associated with age in DS (rho=0.56; p <0.001) than in HC (rho=0.38, p <0.001; Figure 1A), with regression lines starting to diverge at age 42.
• No significant effects were found for sex, APOEε4 status, intellectual disability, or VRF (Figure 1C‐D‐E).
• These findings underscore the potential of PSMD as a sensitive biomarker for detecting early WM alterations in adults with DS.

Why it matters

This cross-sectional study found that a diffusion imaging marker of white matter damage increased along the Alzheimer's continuum in people with Down syndrome and changed about 10-15 years before symptoms. It suggests the marker may help detect early white matter changes, but it does not test any treatment, cure or prevention.

Study details

• Participants70
• Effect size47.14%
• Evidence strengthLow

Read the original

• DOI: 10.1002/alz70856_106537
• Original source →
• Free full text: Alzheimer s & Dementia →

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Down syndrome and Alzheimer's

• Alzheimer-related altered white matter microstructural integrity in Down syndrome: A model for sporadic AD? Alzheimer's & dementia (Amsterdam, Netherlands) · 2020-11-07 · usefulness score 41/100
• Association of plasma neurofilament light chain with microstructural white matter changes in Down syndrome Alzheimer's & dementia (Amsterdam, Netherlands) · 2024-10-01 · usefulness score 48/100
• Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study The Lancet · 2020-06-01 · usefulness score 59/100
• DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome Frontiers in behavioral neuroscience · 2016-06-03 · usefulness score 40/100
• Detection of an Alzheimer disease pattern of cerebral metabolism in Down syndrome Dementia (Basel, Switzerland) · 1994-03-01 · usefulness score 50/100
• Detection of Alzheimer disease in individuals with Down syndrome American journal of mental retardation : AJMR · 1995-05-01 · usefulness score 34/100

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

• Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronal-derived extracellular vesicles Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021-11-23 · usefulness score 50/100 · Down syndrome and Alzheimer's
• Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial Trials · 2016-07-29 · usefulness score 60/100 · Down syndrome and Alzheimer's
• High expression on Kunitz-type protease inhibitor-containing substances in the cerebral vessels of patients with Down syndrome The Tohoku journal of experimental medicine · 1994-11-01 · usefulness score 28/100 · Down syndrome and Alzheimer's

Similar studies

• Evaluation of Memory Changes in Patient with Down Syndrome 2026 · Down syndrome and Alzheimer's
• New approaches to studying early brain development in Down syndrome 2019 · Digital health tools
• Imaging and plasma biomarkers for pathological accumulation in Down syndrome 2026 · Down syndrome and Alzheimer's
• Identification of candidate serum protein biomarkers in Down's syndrome dementia 2025 · Down syndrome and Alzheimer's
• [Biochemical alterations in patients with Down syndrome] 2008 · Down syndrome and Alzheimer's
• Loss of Proteostasis and Early-Onset Neurodegeneration in Down Syndrome: From Mechanisms to Interventions 2026 · Down syndrome and Alzheimer's

More on Down syndrome and Alzheimer's

• A review that covers this ground The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology Alzheimer's & dementia (Amsterdam, Netherlands) · 2020-08-03 · usefulness score 69/100
• Newest in this subject Differential endothelial cell remodeling in Down syndrome and APP duplication drives distinct blood brain barrier dysfunction bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Memory and Plasma pTau217 Refine Prognosis in Down Syndrome Annals of neurology · 2026-10-02 · Peer-reviewed · usefulness score 47/100

See all studies in Down syndrome and Alzheimer's →